علاج سرطان الخلايا القاعدية المتكرر أو عالي الخطورة في الجلد

References

DOI: 10.1016/j.ejca.2023.113254

• Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites.
• Micrographically controlled surgery (3D) shall be offered in high-risk BCC (recurrent, aggressive subtypes, location in critical anatomical sites, poorly defined margins).
• Anti-PD1 immunotherapy should be offered as second-line treatment in patients who progress or have contraindications to hedgehog inhibitors.
• Eighty-four laBCC patients received cemiplimab with the conventional dose of 350 mg intravenously every 3 weeks for up to 93 weeks or until progression or unacceptable toxicity.